Pharma BD Deal Intelligence
AstraZeneca's $1.2B acquisition of Gracell handed it AZD0120, a dual-targeting BCMA/CD19 CAR-T with next-day manufacturing for multiple myeloma and lupus, plus China-based cell-therapy manufacturing. The bet is early but promising, though the therapy remains in development with no approval yet to prove out the price tag.
AstraZeneca acquired Gracell Biotechnologies for $1.2B for cell therapy.
AstraZeneca completes acquisition of Gracell Biotechnologies: $2.00/share cash (~$1.0bn upfront) plus a $0.30/share CVR on a regulatory milestone…
AstraZeneca bolsters cellular therapy pipeline with acquisition of Gracell Biotechnologies and its FasTCAR-enabled technology platform.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
AstraZeneca acquired Nasdaq-listed, China-headquartered clinical-stage cell-therapy company Gracell Biotechnologies in a merger announced 26 December 2023 and completed 22 February 2024. Shareholders received $2.00 per ordinary share (or per ADS) in cash at closing -- an upfront transaction value of approximately $1.0 billion -- plus a non-tradable contingent value right (CVR) of $0.30 per share payable on achievement of a specified regulatory milestone, taking the total potential consideration to approximately $1.2 billion. The acquisition centred on GC012F (now AZD0120), a FasTCAR-enabled, dual-targeting (BCMA and CD19) autologous CAR-T therapy with next-day manufacturing, in development for relapsed/refractory multiple myeloma and B-cell-driven autoimmune disease including systemic lupus erythematosus. The deal expanded AstraZeneca's cell-therapy footprint and added China-based manufacturing and clinical capabilities.
36K US cases/yr · $22.0B US Multiple Myeloma Market
Multiple myeloma is the second most common blood cancer with approximately 35,730 new US cases annually. GC012F is a dual-targeting BCMA/CD19 CAR-T cell therapy built on Gracell FasTCAR platform, which reduces manufacturing from weeks to under 36 hours. AstraZeneca acquired Gracell to strengthen its cell therapy ambitions across oncology and autoimmune diseases.
BCMA-targeting CAR-T therapies have transformed relapsed/refractory myeloma treatment. Carvykti (ciltacabtagene autoleucel, J&J/Legend) and Abecma (idecabtagene vicleucel, BMS/2seventy) are approved competitors. GC012F differentiates through dual BCMA/CD19 targeting and the FasTCAR rapid manufacturing platform. Autoimmune disease application (SLE) represents significant expansion opportunity.
AstraZeneca completed $1.2B acquisition of Gracell Biotechnologies, gaining next-gen CAR-T platform with proprietary FasTCAR manufacturing technology.
AZ leveraged FasTCAR rapid manufacturing for next-gen CAR-T with faster turnaround, advancing clinical programs in hematologic malignancies.
AstraZeneca initiated DURGA-4 (NCT07391657), a Phase 3 open-label randomised trial of AZD0120 vs standard regimens in relapsed/refractory multiple myeloma (Recruiting, start 2026-02-23) -- validating the Gracell acquisition thesis by advancing the FasTCAR BCMA/CD19 CAR-T from Phase 1 to a registrational program.
FasTCAR potentially enables faster/cheaper CAR-T vs competitors. Pipeline advancing but no approvals yet. Long-term platform bet.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Gracell Biotechnologies (this deal) | 2023 | $1.2B | 65 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2023 deals · AstraZeneca PLC deals · Oncology deals